Neuronal pain pathway
The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.
1. A method of treating chronic neuropathic pain in a subject, comprising administering, to a sensory neuron in a dorsal root ganglion of the subject, an effective amount of an agent having formula I:
wherein n is 1, 2 or 3; Z is N or CH;
wherein X represents one of the following functional groups:
wherein Y represents one of the following functional groups:
wherein A represents aryl or heteroaryl groups un-substituted or substituted by one or more lower-alkyl, lower-alkoxy, hydroxy, alkoxy, amino, alkylamino or halogen groups;
wherein R is hydrogen, lower-alkyl, or amidino;
wherein R1, R2, R4, R5 is independently hydrogen, hydroxyl, lower-alkoxy, amino, or halogen; and
wherein R3 is alkyl, aryl, heteroaryl, alkoxy, aryloxy, or a group selected from the following:
wherein R6-R10 are independently hydrogen, hydroxy, lower-alkyl, lower-alkoxy, halogen, trifluoromethyl, carboxy, alkoxycarbonyl, amino, alkylamino, alkylcarbonylamino, alkylsulfonylamino, and tetrazole, so that neuropathic pain in the subject is reduced.
2. The method of claim 1 , wherein the agent is selected from the group consisting of balanol-7R, 14-decarboxy-balanol, and 10-deoxy-balanol.
3. A method of inhibiting long-term hyperexcitability in a damaged sensory neuron in a subject in need thereof, comprising administering, to the sensory neuron, an effective amount of an agent having formula I:
wherein n is 1, 2 or 3; Z is N or CH;
wherein X represents one of the following functional groups:
wherein Y represents one of the following functional groups:
wherein A represents aryl or heteroaryl groups un-substituted or substituted by one or more lower-alkyl, lower-alkoxy, hydroxy, alkoxy, amino, alkylamino or halogen groups; wherein R is hydrogen, lower-alkyl, or amidino;
wherein R1, R2, R4, R5 is independently hydrogen, hydroxyl, lower-alkoxy, amino, or halogen; and
wherein R3 is alkyl, aryl, heteroaryl, alkoxy, aryloxy, or a group selected from the following:
wherein R6-R10 are independently hydrogen, hydroxy, lower-alkyl, lower-alkoxy, halogen, trifluoromethyl, carboxy, alkoxycarbonyl, amino, alkylamino, alkylcarbonylamino, alkylsulfonylamino, and tetrazole, so that neuropathic pain in the subject is reduced.
4. The method of claim 3 , wherein the agent is selected from the group consisting of balano7R, 14-decarboxy-balanol, and 10-deoxy-balanol.
5. A method of treating chronic neuropathic pain in a subject, comprising administering, into the central nervous system of the subject, an effective amount of an agent having formula I:
wherein n is 1, 2 or 3; Z is N or CH;
wherein X represents one of the following functional groups:
wherein Y represents one of the following functional groups:
wherein A represents aryl or heteroaryl groups un-substituted or substituted by one or more lower-alkyl, lower-alkoxy, hydroxy, alkoxy, amino, alkylamino or halogen groups;
wherein R is hydrogen, lower-alkyl, or amidino;
wherein R1, R2, R4, R5 is independently hydrogen, hydroxyl, lower-alkoxy, amino, or halogen; and
wherein R3 is alkyl, aryl, heteroaryl, alkoxy, aryloxy, or a group selected from the following:
wherein R6-R10 are independently hydrogen, hydroxy, lower-alkyl, lower-alkoxy, halogen, trifluoromethyl, carboxy, alkoxycarbonyl, amino, alkylamino, alkylcarbonylamino, alkylsulfonylamino, and tetrazole, so that neuropathic pain in the subject is reduced.
6. The method of claim 5 , wherein the agent is selected from the group consisting of balanol-7R, 14-decarboxy-balanol, and 10-deoxy-balanol.
7. A method of treating chronic neuropathic pain in a subject suffering from peripheral nervous system hyperalgesia, comprising administering, to subject in need of such treatment, an effective amount of an agent having formula I:
wherein X represents one of the following functional groups:
wherein Y represents one of the following functional groups:
wherein A represents aryl or heteroaryl groups un-substituted or substituted by one or more lower-alkyl, lower-alkoxy, hydroxy, alkoxy, amino, alkylamino or halogen groups;
wherein R is hydrogen;
wherein R1, R2, R4, R5 is independently hydrogen, hydroxyl, lower-alkoxy, amino, or halogen; and
wherein R3 is:
wherein R6-R10 are independently hydrogen, hydroxy, lower-alkyl, lower-alkoxy, or halogen, so that neuropathic pain in the subject is reduced.
8. The method of claim 7 wherein the agent is administered to a sensory neuron in a dorsal root ganglion of the subject.
9. The method of claim 7 wherein administration of the agent inhibits long-tern hyperexcitability in a sensory neuron.
10. The method of claim 7 wherein the agent is administered into the central nervous system of the subject.